Johnson & Johnson (JNJ) Stock Price & Analysis
Johnson & Johnson (JNJ) closed at USD 267.61 on Thursday, October 22, 2026, up 3.81% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 257.78; the Oct 22, 2026 session ranged USD 259.04–269.67 on volume of 10,127,910 shares. Market capitalization is $644.91B, with a 52-week range of USD 184.66–281.07 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:23 UTC.
Also available as compact Markdown for AI agents: nexqual.com/JNJ.md
Latest Earnings Results (JNJ)
| Fiscal period | EPS (reported) | Revenue | Released | Source |
|---|---|---|---|---|
| Q3 2026 | $0.09 (GAAP diluted) | $25.40B | Oct 13, 2026, 8:12:35 AM ET · on Nexqual +36 seconds | SEC 8-K filing |
Reported actuals captured by Nexqual from SEC 8-K filings and company press releases; each figure confirmed by two independent extraction methods.
Key facts (JNJ)
- Last four reported quarters (through Sep 27, 2026): revenue $99.3B, net income $16.1B (16.2% margin), free cash flow $20.6B (SEC filings).
- Valuation: P/E 40.1x (avg 18.4x at the last 3 fiscal year-ends), net debt $27.4B.
- Earnings quality: non-operating income -$6.89B vs operating income null over the last four quarters; P/E excluding non-operating income ≈28.9x (estimate: non-operating income taxed at the company's 9.3% effective rate).
- 12 of 80 tracked superinvestors hold JNJ (13F, Q2 2026 (1 investor on Q3 2026, filed early)): 1 new, 1 added, 5 reduced, 5 unchanged.
- Insider open-market sales, last ~7 months: 7 Form 4 filings, $70.2M; 7 not under a Rule 10b5-1 plan ($70.2M); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 2.13 on a 1–5 scale) (23 analysts), mean target USD 279.41 (range 190–320).
- Total return with dividends: 1Y +42.2% vs S&P 500 +14.9%; 5Y +88.0% vs S&P 500 +80.3%.
- Next earnings: 2026-10-13, EPS estimate USD 2.92, revenue estimate $26.4B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (JNJ)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $78.7B | $80.0B | $85.2B | $88.8B | $94.2B | $99.3B |
| Gross profit | $55.3B | $55.4B | $58.6B | $61.4B | $63.9B | — |
| Net income | $20.9B | $17.9B | $35.2B | $14.1B | $26.8B | $16.1B |
| EPS (diluted) | $7.81 | $6.73 | $13.72 | $5.79 | $11.03 | — |
| Free cash flow | $19.8B | $17.2B | $18.2B | $19.8B | $19.7B | $20.6B |
| Gross margin | 70.3% | 69.3% | 68.8% | 69.1% | 67.9% | — |
| Net margin | 26.5% | 22.4% | 41.3% | 15.8% | 28.5% | 16.2% |
| Revenue growth | -4.7% | +1.6% | +6.5% | +4.3% | +6.0% | — |
| Cash + short-term investments | $31.6B | $22.3B | $22.9B | $24.5B | $20.1B | — |
| Total debt | $32.1B | $28.4B | $27.4B | $32.4B | $41.4B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Sep 27, 2026) (JNJ)
P/E 40.1x · P/E ex non-operating (est.) ≈28.9x · P/S 6.5x · EV/Sales 6.8x · P/FCF 31.3x · P/B 7.9x · FCF yield 3.19% · Earnings yield 2.50% · Buyback yield (TTM) 1.22% · Net debt $27.4B · EV $672B
P/E at fiscal year-ends: Dec 2025 18.8x, Dec 2024 25.0x, Dec 2023 11.4x.
Superinvestors (SEC 13F-HR, Q2 2026) (JNJ)
12 of 80 tracked investors hold JNJ (1 investor on Q3 2026, filed early). Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change | Quarter |
|---|---|---|---|---|---|
| Yacktman Asset Management | 3.96% | $320M | Added +0.8% | Q2 2026 | |
| Tweedy Browne | 3.88% | $51.2M | Reduced -8.1% | Q2 2026 | |
| Thomas Gayner | Markel Group | 1.18% | $155M | Unchanged | Q2 2026 |
| Mairs & Power | Mairs & Power Funds | 0.99% | $107M | Reduced -26.8% | Q2 2026 |
| Prem Watsa | Fairfax Financial Holdings | 0.71% | $18.6M | Unchanged | Q2 2026 |
| Torray Funds | 0.14% | $1.1M | Unchanged | Q2 2026 | |
| John Rogers | Ariel Investments | 0.09% | $9.0M | Reduced -12.7% | Q2 2026 |
| Jensen Investment Management | 0.05% | $2.2M | Reduced -9.9% | Q2 2026 | |
| David Katz | Matrix Asset Advisors | 0.04% | $429K | Unchanged | Q3 2026 |
| Christopher Bloomstran | Semper Augustus | 0.02% | $202K | New position | Q2 2026 |
| Dodge & Cox Funds | Dodge & Cox | <0.01% | $5.3M | Unchanged | Q2 2026 |
| Thomas Russo | Gardner Russo & Quinn | <0.01% | $282K | Reduced -14.7% | Q2 2026 |
Insider sales (SEC Form 4, open-market, last ~7 months) (JNJ)
0 of 7 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-09-02 | Schmid Timothy | EVP, WW Chair, MedTech | 33,597 | $9.2M | 56.1% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-08-17 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | 15,000 | $4.0M | 7.2% | No | Too little history (no open-market trades in 2023) |
| 2026-08-13 | Duato Joaquin | CEO and Chairman of the Board | 123,291 | $32.2M | 28.6% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-08-06 | Forminard Elizabeth | EVP, Chief Legal Officer | 15,918 | $4.1M | 48.4% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-08-05 | Duato Joaquin | CEO and Chairman of the Board | 48,480 | $12.5M | 13.6% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-07-20 | Broadhurst Vanessa | EVP, Global Corp Affairs | 23,054 | $5.8M | 50.1% | No | Too little history (no open-market trades in 2023 or 2025) |
| 2026-06-11 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | 10,000 | $2.4M | 8% | No | Too little history (no open-market trades in 2024 or 2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (JNJ)
Consensus Buy (mean 2.13 on a 1–5 scale), 23 analysts; mean target USD 279.41 (low 190, high 320).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-16 | Wells Fargo | Target raised | Overweight | $275 → $287 |
| 2026-10-15 | Morgan Stanley | Target lowered | Overweight | $294 → $292 |
| 2026-10-14 | Leerink Partners | Target lowered | Outperform | $276 → $272 |
| 2026-10-14 | Wells Fargo | Target lowered | Overweight | $282 → $275 |
| 2026-10-14 | RBC Capital | Target lowered | Outperform | $290 → $280 |
| 2026-10-07 | Guggenheim | Reiterated | Buy | $287 |
| 2026-10-06 | RBC Capital | Target raised | Outperform | $287 → $290 |
| 2026-10-05 | Citigroup | Target raised | Buy | $298 → $303 |
| 2026-09-29 | JP Morgan | Target raised | Neutral | $270 → $285 |
| 2026-09-10 | HSBC | Target raised | Buy | $290 → $320 |
| 2026-09-02 | UBS | Target raised | Buy | $280 → $320 |
| 2026-08-06 | Guggenheim | Target raised | Buy | $270 → $287 |
Total return (dividends reinvested) (JNJ)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +42.2% | +88.0% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +42.4% | +13.4% |
| Volatility (annualized) | 20.7% | 17.9% |
| Max drawdown | -11.0% (Mar 2026→May 2026) | -17.4% (Jan 2023→Oct 2023) |
JNJ revenue by business segment (quarter ended Sep 27, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Innovative Medicine | $16.76B | 66.0% | +7.7% |
| MEDTECH | $8.64B | 34.0% | +2.5% |
| Total revenue | $25.40B | 100% | — |
JNJ revenue by region (quarter ended Sep 27, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| United States | $14.96B | 58.9% | +9.1% |
| Non-US | $10.44B | 41.1% | +1.5% |
| — Europe (part of Non-US) | $5.41B | 21.3% | -0.6% |
| — Asia-Pacific, Africa (part of Non-US) | $3.65B | 14.4% | +1.0% |
| — Western Hemisphere, excluding U.S. (part of Non-US) | $1.39B | 5.5% | +12.5% |
| Total revenue | $25.40B | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
JNJ suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | AbbVie (ABBV) | “In 2023, the Centers for Medicare & Medicaid Services (CMS) published the first "Selected Drug" list, which includes XARELTO and STELARA as well as IMBRUVICA, which is developed in collaboration and co-commercialized in the U.S. with Pharmacyclics LLC, an AbbVie company.” |
| Competitor | Merck (MRK) | “The increase in REMICADE (infliximab) sales was due to favorable patient mix, market growth and the Merck, Sharp & Dohme return of rights in Europe in the fiscal fourth quarter of 2024, partially offset by continued biosimilar competition.” |
Quoted from the company's 10-K filed Feb 11, 2026.
Companies that name JNJ in their SEC reports
| Relationship to JNJ | Company | Filing | Sentence |
|---|---|---|---|
| related | Westin Acquisition Corp (WSTN) | 10-K Sep 29, 2026 | “Earlier in his career, Mr. Chung held various sales and management positions at Johnson & Johnson Vision Care, OCBC Bank” |
| competitor | iBio, Inc. (IBIO) | 10-K Aug 28, 2026 | “Our most significant competitors, among others, are fully integrated pharmaceutical companies such as Eli Lilly and Company, Novo Nordisk A/S, Amgen Inc., Bristol-Myers Squibb Company, Merck & Co., Inc., Novartis AG, MedImmune, LLC (a wholly owned subsidiary of AstraZeneca PLC), Johnson & Johnson, Pfizer Inc., Merck KGaA and Sanofi SA, and more established biotechnology companies such as Genentech, Inc. (a member …” |
| competitor | TRINITY BIOTECH PLC (TRIB) | 20-F Apr 30, 2026 | “The Group's competition includes several large companies such as, but not limited to: Abbott Diagnostics, Arkray, Becton Dickenson, Bio-Rad, Copan, Dexcom Inc., Diasorin Inc., Johnson & Johnson, Roche Diagnostics, Sebia, Siemens (from the combined acquisitions of Bayer, Dade-Behring and DPC), Thermo Fisher, Tosoh and Werfen.” |
| partner | Burning Rock Biotech Ltd (BNR) | 20-F Apr 28, 2026 | “Our products are recognized by the medical, pharmaceutical and scientific communities, as evidenced by (i) the use of our products by oncology key opinion leaders in clinical trials and research studies they initiate, and (ii) our collaborations on clinical trials and research studies with leading pharmaceutical companies including AstraZeneca (NYSE: AZN), Bayer (ETR: BAYN), Johnson & Johnson (NYSE: JNJ), CStone (…” |
| partner | MATERIALISE NV (MTLS) | 20-F Apr 23, 2026 | “In the medical market, we have entered into collaborations with DePuy Synthes Companies of Johnson & Johnson, or DePuy Synthes, and Zimmer Biomet Holdings, Inc., or Zimmer Biomet, as well as with Encore Medical, L.P. (d/b/a Enovis), or Enovis, Limacorporate Spa, or Lima, Mathys AG, or Mathys (which is now part of the same company as Enovis), Smith & Nephew Inc., or Smith & Nephew, Corin Ltd, or Corin, Medtronic In…” |
| partner | TuHURA Biosciences, Inc./NV (HURA) | 10-K Mar 31, 2026 | “During his tenure at Johnson & Johnson, Dr. Tendler and his team worked in collaboration with the FDA and the European Medicines Agency to secure worldwide approvals of transformational treatment in prostate cancer, hematologic malignancies, as well as for lunch and bladder cancer.” |
| partner | OMEROS CORP (OMER) | 10-K Mar 31, 2026 | “Earlier in his career, Mr. Ghesquiere served in business development and alliance management roles at Aventis Pharmaceuticals (acquired by Sanofi) and worked in product marketing/new product planning at Johnson & Johnson.” |
| competitor | NEXGEL, INC. (NXGL) | 10-K Mar 31, 2026 | “that actively compete for the business of consumers both in the United States and abroad, including companies such as Johnson & Johnson,” |
| competitor | Alvotech (ALVO) | 20-F Mar 31, 2026 | “In addition to Johnson & Johnson's (the originator's) reference product, we can face competition from other approved biosimilars for Stelara (ustekinumab) in the U.S. and EEA, including biosimilars from Intas, Amgen, Biocon, Celltrion, Formycon, Fresenius Kabi, Gedeon Richter, Samsung Bioepis, Accord and Bio-Thera.” |
| partner | Nanobiotix S.A. (NBTX) | 20-F Mar 31, 2026 | “In July 2023, we entered into a global licensing agreement (Janssen Agreement) with Janssen Pharmaceutica NV ("Janssen"), a Johnson & Johnson” |
| competitor | MiNK Therapeutics, Inc. (INKT) | 10-K Mar 31, 2026 | “Key competitors developing autologous CAR-T and TCR-based therapies include large pharmaceutical and biotechnology companies such as Bristol-Myers Squibb (including former Celgene and Juno Therapeutics assets), Gilead Sciences, Johnson & Johnson, Novartis, AstraZeneca, and BioNTech.” |
| partner | MeiraGTx Holdings plc (MGTX) | 10-K Mar 30, 2026 | “On January 30, 2019, we and our wholly-owned subsidiary MeiraGTx UK II Limited entered into a Collaboration, Option and License Agreement with Johnson & Johnson Innovative Medicine (formerly known as Janssen Pharmaceuticals, Inc.), as further amended by that certain First Amendment to Collaboration, Option and License Agreement, dated as of December 16, 2021 (the "Collaboration Agreement"), for, among other things…” |
| partner | Eikon Therapeutics, Inc. (EIKN) | 10-K Mar 30, 2026 | “At Veracyte, he led collaborations with companies such as Bayer AG, AstraZeneca plc, and Johnson & Johnson, Inc., and orchestrated multiple acquisitions.” |
| competitor | Vor Biopharma Inc. (VOR) | 10-K Mar 30, 2026 | “The autoimmune field is a competitive landscape involving multiple fusion protein class members (atacicept, povetacicept), monoclonal antibodies, other biologics, chimeric antigen receptor (CAR) T cells and small molecules either already marketed or in development by many different companies including, but not limited to Alexion, Amgen, Argenx, Dianthus, Johnson & Johnson, UCB, and Vertex.” |
| partner | Lexeo Therapeutics, Inc. (LXEO) | 10-K Mar 30, 2026 | “Abiomed, Inc. (Johnson & Johnson subsidiary)—In December 2025, the Company entered into a Collaboration Agreement with Abiomed, Inc. ("Abiomed" and the "Abiomed Agreement"), to investigate localized cardiac delivery of gene therapy.” |
JNJ company outlook (results filed Oct 13, 2026)
- “Full-year 2026 guidance: Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses, and purchase accounting fair value adjustments without unreasonable effort.”
Quoted word-for-word from the SEC 8-K results press release.
JNJ analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Dec 2026) | $2.92 | $3.01 | -3.2% | $26.43B | 17 |
| Next quarter (ends Mar 2027) | $2.68 | $2.93 | -8.5% | $25.60B | 7 |
| Current fiscal year (ends Dec 2026) | $11.12 | $11.66 | -4.6% | $101.22B | 21 |
| Next fiscal year (ends Dec 2027) | $11.62 | $12.83 | -9.4% | $107.80B | 22 |
JNJ options: expected move
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Oct 30, 2026 | 7 | 26.2% | ±3.1% |
| Nov 6, 2026 | 14 | 26.3% | ±4.3% |
| Nov 13, 2026 | 21 | 25.7% | ±5.1% |
| Nov 20, 2026 | 28 | 25.9% | ±5.8% |
| Nov 27, 2026 | 35 | 24.5% | ±6.3% |
| Dec 4, 2026 | 42 | 24.3% | ±6.8% |
| Dec 18, 2026 | 56 | 24.6% | ±7.8% |
| Jan 15, 2027 | 84 | 24.0% | ±9.3% |
30-day implied volatility 25.5% vs 26.5% realized over the last 30 trading days. Put/call ratio (volume) 0.83. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:23 UTC)
| Price | USD 267.61 |
|---|---|
| Change | ▲ 3.81% (up) |
| Previous Close | USD 257.78 |
| Open | USD 260.54 |
| Day Range | USD 259.04 – 269.67 |
| 52-Week Range | USD 184.66 – 281.07 |
| Volume | 10,127,910 shares |
| Market Cap | $644.91B |
| Exchange | NYQ |
Technical Analysis (JNJ)
Nexqual's technical model rates JNJ "BUY" based on 4 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 09:23 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 55.67 (neutral) |
| vs SMA50 | Above (USD 265.17) |
| MACD | -1.68 (negative) |
Analyst Ratings (JNJ)
Wall Street analysts rate JNJ "Buy" based on 23 analysts, with a mean price target of USD 279.41 (range USD 190–320), per Nexqual as of October 23, 2026 at 09:23 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 23 |
| Mean Target | USD 279.41 |
| High Target | USD 320 |
| Low Target | USD 190 |
| Buy / Hold / Sell | 16 / 6 / 1 |
Earnings (JNJ)
| Next Earnings Date | 2026-10-13 |
|---|---|
| EPS Estimate | USD 2.92 |
| Revenue Estimate | $26.43B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-09-30 | USD 2.59 vs est 2.52 ▲ beat |
| 2026-06-30 | USD 2.9 vs est 2.85 ▲ beat |
| 2026-03-31 | USD 2.7 vs est 2.68 ▲ beat |
| 2025-12-31 | USD 2.46 vs est 2.46 ▼ miss |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Financials & Fundamentals (JNJ)
| Total Revenue | $99.33B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +5.90% |
| Gross Margin | +67.75% |
| Operating Margin | +25.06% |
| Profit Margin | +16.20% |
| Debt / Equity | 0.58 |
| Total Cash | $20.76B |
| Total Debt | $49.04B |
| Free Cash Flow (last four quarters to Sep 2026, SEC 10-Q / 10-K) | $20.59B (20.7% of revenue) |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Financial Health Score (JNJ)
Nexqual rates Johnson & Johnson's overall financial health "Solid" across five dimensions, as of October 23, 2026 at 09:23 UTC.
| Growth | Solid — Revenue +6% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 68%, operating 25% (last 12 months) |
| Balance Sheet | Solid — $17.2B cash and investments vs $44.7B debt (Sep 2026, SEC) |
| Cash Flow | Strong — FCF $20.6B (last 4 quarters to Sep 2026, SEC), 21% margin |
| Efficiency | Mixed — No data |
Ownership (JNJ)
| Insider Ownership | +0.05% |
|---|---|
| Institutional Ownership | +76.82% |
| Shares Outstanding | 2.41B |
| Float | 2.41B |
| Short % of Float | +1.02% |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Leadership (JNJ)
Johnson & Johnson is led by Joaquin Duato, CEO & Chairman, per Nexqual as of October 23, 2026 at 09:23 UTC.
| CEO & Chairman | Joaquin Duato |
|---|---|
| Executive VP & CFO | Joseph James Wolk |
| Executive Vice President of Innovative Medicine and R & D | John C. Reed |
| Executive VP & Worldwide Chairman of MedTech | Timothy Schmid |
| Vice President of Investor Relations | Ryan Koors |
Major Backers & Investors (JNJ)
Notable institutional backers of Johnson & Johnson include JPMorgan, Morgan Stanley, NORGES BANK, according to Nexqual as of October 23, 2026 at 09:23 UTC.
Active Investors
| Investor | Stake |
|---|---|
| JPMorgan | 2.42% |
| Morgan Stanley | 1.86% |
| NORGES BANK | 1.32% |
| State Farm Mutual Automobile Insurance Co | 1.31% |
| Fidelity | 1.3% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 9.19% |
| BlackRock | 8.8% |
| State Street | 5.55% |
| Geode Capital | 2.45% |
| Northern Trust | 1.19% |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
From Johnson & Johnson's Latest SEC 10-K Filing (filed 2026-02-11)
Partnerships
- In January 2026, the Company reached an agreement with the U.S.
- Many of these medicines were developed in collaboration with strategic partners or are licensed from other companies and maintain active lifecycle development programs.
Legal & Regulatory Risks (Item 1A, quoted)
- The Company is subject to an increasing number of costly and complex governmental regulations in the countries in which operations are conducted which may have a material adverse affect on the Company's financial condition and business operations.
- The Company is subject to significant legal proceedings that can result in significant expenses, fines and reputational damage.
- Product reliability, safety and effectiveness concerns can have significant negative impacts on sales and results of operations, lead to litigation and cause reputational damage.
- Product concerns, whether raised internally or by litigants, regulators or consumer advocates, and whether or not based on scientific evidence, can result in safety alerts, field actions, such as product recalls, governmental investigations, regulatory action on the part of the U.S.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ABBV | AbbVie Inc. | USD 285.19 | ▲ 0.14% |
| MRK | Merck & Company, Inc. | USD 147.24 | ▼ 1.76% |
| LLY | Eli Lilly and Company | USD 1,306.69 | ▲ 2.83% |
| NVS | Novartis AG | USD 156.27 | ▲ 1.52% |
| AZN | AstraZeneca PLC | USD 172.57 | ▲ 2.45% |
| AMGN | Amgen Inc. | USD 447.28 | ▲ 2.04% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:23 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt